we report that the BR regimen remains a highly effective treatment option for untreated WM patients even in the era of BTKis. This regimen showed a high ORR and exhibited excellent PFS even when the initial bendamustine dose was reduced to 70 mg/m2 and dose intensity was decreased up to 30% from the initial dose. Only in case of a relative dose intensity reduction of >30%, the PFS of BR-treated patients was comparable to those treated with DRC. Age over 75 years and CrCl lower than 70 mmol/L were the main risk factors for this significant dose reduction. Patients with these characteristics are likely to benefit less from the BR regimen and should be considered for alternative treatments.
First-line treatment of Waldenström's macroglobulinemia in Italy: A multicenter real-life study on 547 patients to evaluate the long-term efficacy and tolerability of different chemoimmunotherapy strategies
Tedeschi, A;Galli, E;Rizzi, R;Ferrarini, I;Petrilli, D;Scapinello, G;
2025-01-01
Abstract
we report that the BR regimen remains a highly effective treatment option for untreated WM patients even in the era of BTKis. This regimen showed a high ORR and exhibited excellent PFS even when the initial bendamustine dose was reduced to 70 mg/m2 and dose intensity was decreased up to 30% from the initial dose. Only in case of a relative dose intensity reduction of >30%, the PFS of BR-treated patients was comparable to those treated with DRC. Age over 75 years and CrCl lower than 70 mmol/L were the main risk factors for this significant dose reduction. Patients with these characteristics are likely to benefit less from the BR regimen and should be considered for alternative treatments.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
